Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bio-Techne Corp (TECH) Return on equity
Bio-Techne Corp's return on equity over the twelve months to 30 June 2026 was 9.03%. Over the past ten years it has ranged from 3.68% (fiscal 2025) to 18.0% (fiscal 2020); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of −57.7% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | 9.03% | 5.35 |
| FY2025 | 3.68% | (4.65) |
| FY2024 | 8.33% | (7.23) |
| FY2023 | 15.6% | (1.07) |
| FY2022 | 16.6% | 7.12 |
| FY2021 | 9.51% | (8.50) |
| FY2020 | 18.0% | 9.45 |
| FY2019 | 8.56% | (3.88) |
| FY2018 | 12.4% | 4.12 |
| FY2017 | 8.32% | (3.78) |
Against its own ten years
Low 3.68%
High 18.0%
Ten-year median
10.8%
Current reading's percentile
42
Return on equity against peers
| Company | Return on equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | 173.7% |
| BBIO BridgeBio Pharma, Inc. compare | 32.3% |
| KRYS Krystal Biotech, Inc. compare | 20.1% |
| TECH Bio-Techne Corp | 9.03% |
| CORT Corcept Therapeutics Incorporated compare | 8.08% |
| BMRN BioMarin Pharmaceutical Inc. compare | 1.18% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −53.3% |
| SMMT Summit Therapeutics PLC compare | −192.5% |
| AXSM Axsome Therapeutics, Inc. compare | −245.1% |
| Biotechnology industry median | −57.7% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TECH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement